Innovative Immunotherapies OncoPep specializes in T cell focused immunotherapeutics, including multi-peptide vaccines and adoptive T cell therapies, positioning them as a promising partner for healthcare providers seeking novel cancer treatment options.
Recent Funding Boost The company secured an $11 million Series D financing in December 2021, indicating strong investor confidence and potential for expanding clinical development and partnerships.
Leadership Expansion With the hiring of experienced medical and scientific leaders like Chief Medical Officer Victor Moyo and addition of prominent advisors, OncoPep is strengthening its expertise and credibility in the oncology immunotherapy space.
Partnership Capabilities OncoPep’s licensing agreement with MANA Therapeutics demonstrates its collaboration capability, opening avenues for joint development, licensing, and co-marketing opportunities with other biotech and pharmaceutical entities.
Growth Potential Although currently in early revenue stages with up to 1 million dollars, OncoPep’s focused pipeline and strategic funding position it well for growth, especially as innovative oncology therapies gain market traction.
$1M$10M
$100M$250M
$1B$10B
$1M$10M
$1M$10M
$25M$50M
$10M$25MOncoPep, Inc. uses 8 technology products and services including QuickBooks, CookieYes, Microsoft Excel, and more. Explore OncoPep, Inc.'s tech stack below.
| OncoPep, Inc. Email Formats | Percentage |
| FLast@oncopep.com | 100% |
Biotechnology ResearchMassachusetts, United States2-10 Employees
Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell focused technologies are designed to be used on their own or in combination with other immunotherapeutics.
Company Overview
Funding & FinancialsOncoPep, Inc.'s revenue is estimated to be in the range of $1M
Funding & FinancialsOncoPep, Inc.'s revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com